Pilot study of denosumab in BRCA1/2 mutation carriers scheduled for risk-reducing salpingo-oopherectomy
Ended Awarded Last action
- Contract number
- HHSN26100013
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $262,986
Award facts
- Contract value 27% obligated
-
- $262,985.58 Current, with exercised options
- $976,432.58 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$261,452 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Original award | $524,438 |
About this award
This is a federal contract award from the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a pilot study of the drug denosumab in BRCA1/2 mutation carriers scheduled for risk-reducing salpingo-oophorectomy. The $976,432.58 cost-reimbursement contract is part of the NCI's Cancer Prevention Agent Development Program, supporting early phase clinical research. It was awarded on September 21, 2017 with a performance period through December 31, 2022. The contract does not have a set-aside designation. MD Anderson is the prime contractor with no major subcontractors identified. This award aligns with the NCI's mission to support research into new cancer prevention and treatment strategies.
Quick answers
Who was awarded contract HHSN26100013?
HHSN26100013 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 21, 2017.
How much is contract HHSN26100013 worth?
The government has obligated $262,986 on HHSN26100013. Its potential value, with all options, is $976,433.
Is contract HHSN26100013 an order under another contract?
Yes. HHSN26100013 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100013 competed?
The extent of competition for HHSN26100013 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award